Semaglutide
Also known as: Ozempic · Wegovy · Rybelsus
A long-acting GLP-1 receptor agonist licensed for type-2 diabetes and obesity, with Phase III Alzheimer's disease trials (EVOKE and EVOKE Plus) that did not show slowed clinical progression (Lancet, 2026).
Semaglutide is a licensed long-acting GLP-1 receptor agonist (Ozempic/Wegovy/Rybelsus) with Phase III Alzheimer's trials (EVOKE, EVOKE Plus) that did not show slowed clinical progression (Lancet, 2026).
Evidence tier: A — ≥1 RCT + meta-analysis or approved clinical use
- Category
- Neuroprotection
- Half-life
- Approximately 7 days plasma (extended-acting formulation)
Section 1
Overview
Semaglutide is a synthetic long-acting analogue of glucagon-like peptide-1 (GLP-1), engineered for extended plasma half-life through fatty-acid modification and altered amino-acid substitution at the DPP-4 cleavage site. It is an authorised pharmaceutical (Ozempic, Wegovy, Rybelsus) for type-2 diabetes and weight management in the UK (emc) and the EU (EMA), and Drugs@FDA lists Ozempic, Rybelsus and Wegovy as approved, with a substantial post-marketing safety database from millions of patients.
The compound's relevance to cognitive research is emerging rather than established. Population-level observational data — including analyses of large databases like the US TriNetX network — have consistently shown reduced incidence of Alzheimer's disease and other dementias in semaglutide-treated diabetic populations versus comparator diabetes drugs. The mechanism-of-action rationale is plausible: GLP-1 receptor agonism has documented effects on brain glucose metabolism, insulin signalling, neuroinflammation, and BDNF expression, all of which are relevant to cognitive-decline pathophysiology.
The definitive test was the EVOKE trial programme — two Phase III randomised, double-blind, placebo-controlled trials of oral semaglutide in early Alzheimer's disease (NCT04777396 and NCT04777409), with a primary outcome of change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score from baseline to week 104. The published report (Cummings et al., Lancet 2026, doi 10.1016/S0140-6736(26)00459-9) concluded that oral semaglutide 14 mg was not efficacious in slowing clinical progression in early Alzheimer's disease (mean change in CDR-SB from baseline to week 104 was 2.3 (EVOKE) and 2.2 (EVOKE Plus) with semaglutide against 2.3 and 2.1 with placebo), and both trials were discontinued for negative clinical outcome.
Section 2
Discovery & History
- Developed by Novo Nordisk as a long-acting GLP-1 receptor agonist analogue of exenatide and liraglutide, with the specific structural modifications designed to achieve once-weekly subcutaneous dosing.
- Received FDA approval in December 2017 for type-2 diabetes (Ozempic). Subsequent approvals for obesity (Wegovy, 2021) and oral formulation (Rybelsus, 2019) expanded the clinical footprint dramatically.
- Population-level cognitive-endpoint observational data emerged from 2020 onwards, with multiple independent analyses showing reduced dementia incidence in semaglutide-treated cohorts versus diabetes-drug comparators.
- The EVOKE and EVOKE Plus Phase III Alzheimer's trials started on 18 May 2021 and are listed on ClinicalTrials.gov as completed (completion date 30 January 2026); the Lancet report (2026) found that oral semaglutide was not efficacious in slowing clinical progression in early Alzheimer's disease.
- The peptide's inclusion on this reference is provisional — its cognitive-relevance evidence base rests on population-level associations and preclinical mechanistic work; the EVOKE Phase III trials did not show slowed clinical progression in early Alzheimer's disease (Lancet, 2026).
Section 3
Mechanism of Action
- 1Direct GLP-1 receptor agonism — sustained receptor activation drives multiple downstream effects across metabolic, cardiovascular, and central-nervous-system targets.
- 2Central GLP-1 receptor activation — GLP-1 receptors are expressed on multiple CNS neuronal populations including in the hippocampus, providing the anatomical substrate for direct cognitive effects.
- 3Improvement of central insulin signalling and brain glucose utilisation — the mechanism-of-action angle for Alzheimer's disease, which has been characterised as a 'type 3 diabetes' with central insulin resistance as a core pathophysiological feature.
- 4Reduction of neuroinflammation — measurable effects on microglial activation, cytokine expression, and neuroinflammatory markers in animal models and preclinical work.
- 5Induction of BDNF expression in hippocampus and cortex in animal models, providing a link to the BDNF-mediated cognitive-plasticity pathway that dominates the cognitive-peptide field.
- 6Reduction of amyloid-beta accumulation and tau-pathology markers in transgenic Alzheimer's model animals — the mechanistic scaffold for the disease-modifying-drug positioning in AD.
- 7Cardiovascular and metabolic-syndrome effects — reduced cardiovascular events, improved lipid profile, weight reduction — that indirectly reduce the vascular-and-metabolic contribution to cognitive decline.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Licensed clinical use in type-2 diabetes with substantial glycaemic-control benefits and reduced cardiovascular events.
- 2Licensed clinical use in obesity with substantial weight-reduction efficacy (~15% body-weight reduction over 68 weeks in Phase III trials).
- 3Population-level observational data supporting reduced dementia incidence in treated diabetic populations.
- 4Preclinical mechanistic support for cognitive-disease-modifying activity in Alzheimer's disease models.
- 5Studied in a Phase III trial programme (EVOKE and EVOKE Plus) in early Alzheimer's disease, which did not show slowed clinical progression (Lancet, 2026).
- 6Substantial acute and long-term safety database from millions of licensed-indication patient-years.
- 7Cardiovascular and metabolic-syndrome benefits that indirectly reduce vascular-cognitive-impairment risk.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Subcutaneous injection (Ozempic) | Licensed dose for type 2 diabetes mellitus (SmPC): start 0.25 mg once weekly; after 4 weeks 0.5 mg; after at least 4 weeks 1 mg; after at least a further 4 weeks 2 mg if needed. Weekly doses above 2 mg are not recommended | Once weekly | Dose steps of at least 4 weeks, as set out in the SmPC | emc SmPC: Ozempic (section 4.2) |
| Subcutaneous injection (Wegovy) | Licensed dose for weight management (SmPC): start 0.25 mg once weekly, escalated over 16 weeks (0.25, 0.5, 1 and 1.7 mg, 4 weeks each) to a maintenance dose of 2.4 mg once weekly; in adults with obesity 7.2 mg once weekly if needed after at least 4 weeks on 2.4 mg | Once weekly | 16-week escalation, then maintenance, as set out in the SmPC | emc SmPC: Wegovy 2.4 mg FlexTouch (section 4.2) |
| Oral (Rybelsus) | Licensed dose for type 2 diabetes mellitus (SmPC, 3/7/14 mg tablets): start 3 mg once daily for one month; then 7 mg; after at least a further month 14 mg if needed. The maximum recommended single daily dose is 14 mg | Once daily | Dose steps of at least one month, as set out in the SmPC | emc SmPC: Rybelsus 3 mg (section 4.2) |
Note: Not approved for cognitive indications. Cognitive-endpoint clinical use is investigational; the EVOKE Phase III trials did not show slowed clinical progression in early Alzheimer's disease (Lancet, 2026).
Note: Not approved for cognitive indications.
Note: The oral formulation is the one evaluated in the EVOKE cognitive-endpoint trials; the injectable and oral forms have overlapping but not identical pharmacokinetics. Rybelsus 1.5/4/9 mg tablets have a separate emc SmPC with different dose steps.
Section 6
Administration Routes
- Subcutaneous once-weekly injection — the primary route in the licensed indications (Ozempic, Wegovy).
- Oral once-daily administration in the licensed indication (Rybelsus) and in the EVOKE cognitive-endpoint trials.
- The oral formulation exploits a proprietary absorption-enhancer (SNAC / sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to achieve meaningful oral bioavailability from an otherwise gut-degraded peptide.
- No intranasal or transdermal delivery form exists in clinical use.
Section 7
Safety Profile
Commonly reported
- · Gastrointestinal adverse effects — nausea, vomiting, diarrhoea, constipation — are the most common tolerability signal and the principal reason for discontinuation.
- · Injection-site reactions with subcutaneous administration; typically mild and self-limiting.
- · Reduced appetite and satiety effects — the pharmacology behind the weight-loss indication and expected in all patients on the compound.
- · Occasional headache, fatigue, and dizziness during dose titration.
- · Mild transient effects on heart rate reported at low frequency.
Rare / theoretical
- · Acute pancreatitis — reported at low but non-zero frequency in the licensed clinical experience; requires discontinuation and clinical evaluation if suspected.
- · Gallbladder disease and cholelithiasis — increased risk related to rapid weight loss.
- · Thyroid C-cell tumours — theoretical concern from rodent carcinogenicity studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
- · Diabetic retinopathy complications reported at low frequency in the diabetes population.
- · Rare reports of severe hypoglycaemia in combination with sulphonylureas or insulin.
Contraindications
- · Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome.
- · Type 1 diabetes and diabetic ketoacidosis.
- · Pregnancy and breastfeeding.
- · Severe gastrointestinal disease including severe gastroparesis.
- · Concurrent use with other GLP-1 receptor agonists — pharmacodynamic redundancy.
Section 8
UK & EU Regulatory Context
United Kingdom
Authorised in the UK as prescription-only medicines: the electronic medicines compendium (emc) lists Ozempic and Rybelsus (type 2 diabetes mellitus) and Wegovy (weight management), checked 17 October 2026. Cognitive indications are not among the indications listed in the Ozempic or Wegovy SmPC.
European Union
Approved by the EMA for type-2 diabetes and weight management. Not approved for cognitive indications.
Section 9
Clinical Studies Summary
Semaglutide in Alzheimer's disease — EVOKE and EVOKE Plus Phase III trials
Two Phase III randomised, double-blind, placebo-controlled trials of oral semaglutide (up to 14 mg once daily) in early Alzheimer's disease, with 3,808 participants randomised (1,855 in EVOKE, 1,953 in EVOKE Plus). Primary endpoint: change in CDR-SB from baseline to week 104. mean change in CDR-SB from baseline to week 104 was 2.3 (EVOKE) and 2.2 (EVOKE Plus) with semaglutide against 2.3 and 2.1 with placebo; the authors concluded oral semaglutide was not efficacious in slowing clinical progression, and both trials were discontinued for negative clinical outcome.
Read studySemaglutide and dementia risk in population-level observational data
Multiple independent analyses of large healthcare databases (TriNetX and similar) reporting reduced incidence of Alzheimer's disease and other dementias in semaglutide-treated type-2 diabetes cohorts versus comparator diabetes drugs. The observational evidence base that motivated the EVOKE Phase III programme.
GLP-1 receptor agonism and central insulin signalling
Mechanistic characterisation of GLP-1 receptor expression and signalling in the CNS, demonstrating improved central insulin signalling, reduced neuroinflammation, and increased BDNF expression in preclinical models. The mechanism-of-action scaffold for the AD cognitive-therapeutic research angle.
Semaglutide cardiovascular and metabolic outcome trials (SUSTAIN, PIONEER)
Multiple large randomised trials establishing the compound's cardiovascular safety and metabolic efficacy in type-2 diabetes populations, providing the licensed-indication evidence base and the substantial post-marketing safety database.
Section 10
Frequently Asked Questions
Section 10a